1. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide
- Author
-
C Cormier, C J Menkes, and B Godeau
- Subjects
Systemic disease ,medicine.medical_specialty ,Cyclophosphamide ,Prednisolone ,medicine.medical_treatment ,Immunology ,Administration, Oral ,Bronchiolitis obliterans ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Rheumatology ,Prednisone ,Internal medicine ,medicine ,Humans ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Bronchiolitis Obliterans ,Chemotherapy ,Lupus erythematosus ,business.industry ,Respiratory disease ,Middle Aged ,medicine.disease ,Surgery ,Injections, Intravenous ,Drug Therapy, Combination ,Female ,business ,medicine.drug ,Research Article - Abstract
A 49 year old white woman with systemic lupus erythematosus and bronchiolitis obliterans was treated with prednisone (1 mg/kg daily), which led to a transitory improvement in pulmonary status. Cyclophosphamide was then added--4 mg/kg daily intravenously for five days, then 2 mg/kg daily orally--and this was followed by a dramatic and prolonged improvement.
- Published
- 1991